Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition
It is well understood that the adaptive immune response to infectious agents includes a modulating suppressive component as well as an activating component. We now show that the very early innate response also has an immunosuppressive component. Infected cells upregulate the CD47 "don't ea...
Saved in:
| Published in | mBio Vol. 11; no. 3 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
23.06.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | It is well understood that the adaptive immune response to infectious agents includes a modulating suppressive component as well as an activating component. We now show that the very early innate response also has an immunosuppressive component. Infected cells upregulate the CD47 "don't eat me" signal, which slows the phagocytic uptake of dying and viable cells as well as downstream antigen-presenting cell (APC) functions. A CD47 mimic that acts as an essential virulence factor is encoded by all poxviruses, but CD47 expression on infected cells was found to be upregulated even by pathogens, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that encode no mimic. CD47 upregulation was revealed to be a host response induced by the stimulation of both endosomal and cytosolic pathogen recognition receptors (PRRs). Furthermore, proinflammatory cytokines, including those found in the plasma of hepatitis C patients, upregulated CD47 on uninfected dendritic cells, thereby linking innate modulation with downstream adaptive immune responses. Indeed, results from antibody-mediated CD47 blockade experiments as well as CD47 knockout mice revealed an immunosuppressive role for CD47 during infections with lymphocytic choriomeningitis virus and
Since CD47 blockade operates at the level of pattern recognition receptors rather than at a pathogen or antigen-specific level, these findings identify CD47 as a novel potential immunotherapeutic target for the enhancement of immune responses to a broad range of infectious agents.
Immune responses to infectious agents are initiated when a pathogen or its components bind to pattern recognition receptors (PRRs). PRR binding sets off a cascade of events that activates immune responses. We now show that, in addition to activating immune responses, PRR signaling also initiates an immunosuppressive response, probably to limit inflammation. The importance of the current findings is that blockade of immunomodulatory signaling, which is mediated by the upregulation of the CD47 molecule, can lead to enhanced immune responses to any pathogen that triggers PRR signaling. Since most or all pathogens trigger PRRs, CD47 blockade could be used to speed up and strengthen both innate and adaptive immune responses when medically indicated. Such immunotherapy could be done without a requirement for knowing the HLA type of the individual, the specific antigens of the pathogen, or, in the case of bacterial infections, the antimicrobial resistance profile. |
|---|---|
| AbstractList | Immune responses to infectious agents are initiated when a pathogen or its components bind to pattern recognition receptors (PRRs). PRR binding sets off a cascade of events that activates immune responses. We now show that, in addition to activating immune responses, PRR signaling also initiates an immunosuppressive response, probably to limit inflammation. The importance of the current findings is that blockade of immunomodulatory signaling, which is mediated by the upregulation of the CD47 molecule, can lead to enhanced immune responses to any pathogen that triggers PRR signaling. Since most or all pathogens trigger PRRs, CD47 blockade could be used to speed up and strengthen both innate and adaptive immune responses when medically indicated. Such immunotherapy could be done without a requirement for knowing the HLA type of the individual, the specific antigens of the pathogen, or, in the case of bacterial infections, the antimicrobial resistance profile.
It is well understood that the adaptive immune response to infectious agents includes a modulating suppressive component as well as an activating component. We now show that the very early innate response also has an immunosuppressive component. Infected cells upregulate the CD47 “don’t eat me” signal, which slows the phagocytic uptake of dying and viable cells as well as downstream antigen-presenting cell (APC) functions. A CD47 mimic that acts as an essential virulence factor is encoded by all poxviruses, but CD47 expression on infected cells was found to be upregulated even by pathogens, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that encode no mimic. CD47 upregulation was revealed to be a host response induced by the stimulation of both endosomal and cytosolic pathogen recognition receptors (PRRs). Furthermore, proinflammatory cytokines, including those found in the plasma of hepatitis C patients, upregulated CD47 on uninfected dendritic cells, thereby linking innate modulation with downstream adaptive immune responses. Indeed, results from antibody-mediated CD47 blockade experiments as well as CD47 knockout mice revealed an immunosuppressive role for CD47 during infections with lymphocytic choriomeningitis virus and
Mycobacterium tuberculosis
. Since CD47 blockade operates at the level of pattern recognition receptors rather than at a pathogen or antigen-specific level, these findings identify CD47 as a novel potential immunotherapeutic target for the enhancement of immune responses to a broad range of infectious agents. It is well understood that the adaptive immune response to infectious agents includes a modulating suppressive component as well as an activating component. We now show that the very early innate response also has an immunosuppressive component. Infected cells upregulate the CD47 "don't eat me" signal, which slows the phagocytic uptake of dying and viable cells as well as downstream antigen-presenting cell (APC) functions. A CD47 mimic that acts as an essential virulence factor is encoded by all poxviruses, but CD47 expression on infected cells was found to be upregulated even by pathogens, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that encode no mimic. CD47 upregulation was revealed to be a host response induced by the stimulation of both endosomal and cytosolic pathogen recognition receptors (PRRs). Furthermore, proinflammatory cytokines, including those found in the plasma of hepatitis C patients, upregulated CD47 on uninfected dendritic cells, thereby linking innate modulation with downstream adaptive immune responses. Indeed, results from antibody-mediated CD47 blockade experiments as well as CD47 knockout mice revealed an immunosuppressive role for CD47 during infections with lymphocytic choriomeningitis virus and Since CD47 blockade operates at the level of pattern recognition receptors rather than at a pathogen or antigen-specific level, these findings identify CD47 as a novel potential immunotherapeutic target for the enhancement of immune responses to a broad range of infectious agents. Immune responses to infectious agents are initiated when a pathogen or its components bind to pattern recognition receptors (PRRs). PRR binding sets off a cascade of events that activates immune responses. We now show that, in addition to activating immune responses, PRR signaling also initiates an immunosuppressive response, probably to limit inflammation. The importance of the current findings is that blockade of immunomodulatory signaling, which is mediated by the upregulation of the CD47 molecule, can lead to enhanced immune responses to any pathogen that triggers PRR signaling. Since most or all pathogens trigger PRRs, CD47 blockade could be used to speed up and strengthen both innate and adaptive immune responses when medically indicated. Such immunotherapy could be done without a requirement for knowing the HLA type of the individual, the specific antigens of the pathogen, or, in the case of bacterial infections, the antimicrobial resistance profile. Immune responses to infectious agents are initiated when a pathogen or its components bind to pattern recognition receptors (PRRs). PRR binding sets off a cascade of events that activates immune responses. We now show that, in addition to activating immune responses, PRR signaling also initiates an immunosuppressive response, probably to limit inflammation. The importance of the current findings is that blockade of immunomodulatory signaling, which is mediated by the upregulation of the CD47 molecule, can lead to enhanced immune responses to any pathogen that triggers PRR signaling. Since most or all pathogens trigger PRRs, CD47 blockade could be used to speed up and strengthen both innate and adaptive immune responses when medically indicated. Such immunotherapy could be done without a requirement for knowing the HLA type of the individual, the specific antigens of the pathogen, or, in the case of bacterial infections, the antimicrobial resistance profile. It is well understood that the adaptive immune response to infectious agents includes a modulating suppressive component as well as an activating component. We now show that the very early innate response also has an immunosuppressive component. Infected cells upregulate the CD47 “don’t eat me” signal, which slows the phagocytic uptake of dying and viable cells as well as downstream antigen-presenting cell (APC) functions. A CD47 mimic that acts as an essential virulence factor is encoded by all poxviruses, but CD47 expression on infected cells was found to be upregulated even by pathogens, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that encode no mimic. CD47 upregulation was revealed to be a host response induced by the stimulation of both endosomal and cytosolic pathogen recognition receptors (PRRs). Furthermore, proinflammatory cytokines, including those found in the plasma of hepatitis C patients, upregulated CD47 on uninfected dendritic cells, thereby linking innate modulation with downstream adaptive immune responses. Indeed, results from antibody-mediated CD47 blockade experiments as well as CD47 knockout mice revealed an immunosuppressive role for CD47 during infections with lymphocytic choriomeningitis virus and Mycobacterium tuberculosis . Since CD47 blockade operates at the level of pattern recognition receptors rather than at a pathogen or antigen-specific level, these findings identify CD47 as a novel potential immunotherapeutic target for the enhancement of immune responses to a broad range of infectious agents. IMPORTANCE Immune responses to infectious agents are initiated when a pathogen or its components bind to pattern recognition receptors (PRRs). PRR binding sets off a cascade of events that activates immune responses. We now show that, in addition to activating immune responses, PRR signaling also initiates an immunosuppressive response, probably to limit inflammation. The importance of the current findings is that blockade of immunomodulatory signaling, which is mediated by the upregulation of the CD47 molecule, can lead to enhanced immune responses to any pathogen that triggers PRR signaling. Since most or all pathogens trigger PRRs, CD47 blockade could be used to speed up and strengthen both innate and adaptive immune responses when medically indicated. Such immunotherapy could be done without a requirement for knowing the HLA type of the individual, the specific antigens of the pathogen, or, in the case of bacterial infections, the antimicrobial resistance profile. ABSTRACT It is well understood that the adaptive immune response to infectious agents includes a modulating suppressive component as well as an activating component. We now show that the very early innate response also has an immunosuppressive component. Infected cells upregulate the CD47 “don’t eat me” signal, which slows the phagocytic uptake of dying and viable cells as well as downstream antigen-presenting cell (APC) functions. A CD47 mimic that acts as an essential virulence factor is encoded by all poxviruses, but CD47 expression on infected cells was found to be upregulated even by pathogens, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that encode no mimic. CD47 upregulation was revealed to be a host response induced by the stimulation of both endosomal and cytosolic pathogen recognition receptors (PRRs). Furthermore, proinflammatory cytokines, including those found in the plasma of hepatitis C patients, upregulated CD47 on uninfected dendritic cells, thereby linking innate modulation with downstream adaptive immune responses. Indeed, results from antibody-mediated CD47 blockade experiments as well as CD47 knockout mice revealed an immunosuppressive role for CD47 during infections with lymphocytic choriomeningitis virus and Mycobacterium tuberculosis. Since CD47 blockade operates at the level of pattern recognition receptors rather than at a pathogen or antigen-specific level, these findings identify CD47 as a novel potential immunotherapeutic target for the enhancement of immune responses to a broad range of infectious agents. IMPORTANCE Immune responses to infectious agents are initiated when a pathogen or its components bind to pattern recognition receptors (PRRs). PRR binding sets off a cascade of events that activates immune responses. We now show that, in addition to activating immune responses, PRR signaling also initiates an immunosuppressive response, probably to limit inflammation. The importance of the current findings is that blockade of immunomodulatory signaling, which is mediated by the upregulation of the CD47 molecule, can lead to enhanced immune responses to any pathogen that triggers PRR signaling. Since most or all pathogens trigger PRRs, CD47 blockade could be used to speed up and strengthen both innate and adaptive immune responses when medically indicated. Such immunotherapy could be done without a requirement for knowing the HLA type of the individual, the specific antigens of the pathogen, or, in the case of bacterial infections, the antimicrobial resistance profile. |
| Author | Nguyen, Thai Corey, Daniel Lopez Angel, Cesar Hasenkrug, Michaela Weissman, Irving L Kortmann, Jens Banaei, Niaz Rajadas, Jayakumar Messer, Ronald J Kalluru, Raja Sab Ahmed, Aijaz Hansen, Paige Winkler, Clayton W Wagh, Dhananjay Lang, Karl S Sahoo, Debashis Torrez Dulgeroff, Laughing Bear Fram, Benjamin J Davis, Mark M Tal, Michal Caspi Markovic, Maxim Cham, Lamin B Glenn, Jeffrey S Peterson, Karin E Castro, Ehydel Yiu, Ying Ying Gars, Eric Galloway, Sarah Monack, Denise M Adomati, Tom Bohrer, Andrea C Mayer-Barber, Katrin D Woods, Tyson A Hasenkrug, Kim J Pham, Ed Carmody, Aaron B Myers, Lara |
| Author_xml | – sequence: 1 givenname: Michal Caspi surname: Tal fullname: Tal, Michal Caspi organization: Ludwig Cancer Center, Stanford University School of Medicine, Stanford, California, USA – sequence: 2 givenname: Laughing Bear surname: Torrez Dulgeroff fullname: Torrez Dulgeroff, Laughing Bear organization: Ludwig Cancer Center, Stanford University School of Medicine, Stanford, California, USA – sequence: 3 givenname: Lara surname: Myers fullname: Myers, Lara organization: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 4 givenname: Lamin B surname: Cham fullname: Cham, Lamin B organization: Institute of Immunology, Medical Faculty, University of Duisburg-Essen, Essen, Germany – sequence: 5 givenname: Katrin D surname: Mayer-Barber fullname: Mayer-Barber, Katrin D organization: Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA – sequence: 6 givenname: Andrea C surname: Bohrer fullname: Bohrer, Andrea C organization: Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA – sequence: 7 givenname: Ehydel surname: Castro fullname: Castro, Ehydel organization: Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA – sequence: 8 givenname: Ying Ying surname: Yiu fullname: Yiu, Ying Ying organization: Ludwig Cancer Center, Stanford University School of Medicine, Stanford, California, USA – sequence: 9 givenname: Cesar surname: Lopez Angel fullname: Lopez Angel, Cesar organization: Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA – sequence: 10 givenname: Ed surname: Pham fullname: Pham, Ed organization: Department of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA – sequence: 11 givenname: Aaron B surname: Carmody fullname: Carmody, Aaron B organization: Research Technologies Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 12 givenname: Ronald J surname: Messer fullname: Messer, Ronald J organization: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 13 givenname: Eric surname: Gars fullname: Gars, Eric organization: Department of Pathology, Stanford University School of Medicine, Stanford, California, USA – sequence: 14 givenname: Jens surname: Kortmann fullname: Kortmann, Jens organization: Genentech Inc., South San Francisco, California, USA – sequence: 15 givenname: Maxim surname: Markovic fullname: Markovic, Maxim organization: Ludwig Cancer Center, Stanford University School of Medicine, Stanford, California, USA – sequence: 16 givenname: Michaela surname: Hasenkrug fullname: Hasenkrug, Michaela organization: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 17 givenname: Karin E surname: Peterson fullname: Peterson, Karin E organization: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 18 givenname: Clayton W surname: Winkler fullname: Winkler, Clayton W organization: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 19 givenname: Tyson A surname: Woods fullname: Woods, Tyson A organization: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA – sequence: 20 givenname: Paige surname: Hansen fullname: Hansen, Paige organization: Ludwig Cancer Center, Stanford University School of Medicine, Stanford, California, USA – sequence: 21 givenname: Sarah surname: Galloway fullname: Galloway, Sarah organization: Ludwig Cancer Center, Stanford University School of Medicine, Stanford, California, USA – sequence: 22 givenname: Dhananjay surname: Wagh fullname: Wagh, Dhananjay organization: Biomaterials and Advanced Drug Delivery Laboratory, Cardio Vascular Institute, Stanford University School of Medicine, Stanford, California, USA – sequence: 23 givenname: Benjamin J surname: Fram fullname: Fram, Benjamin J organization: Department of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA – sequence: 24 givenname: Thai surname: Nguyen fullname: Nguyen, Thai organization: Department of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA – sequence: 25 givenname: Daniel surname: Corey fullname: Corey, Daniel organization: Ludwig Cancer Center, Stanford University School of Medicine, Stanford, California, USA – sequence: 26 givenname: Raja Sab surname: Kalluru fullname: Kalluru, Raja Sab organization: Department of Pathology, Stanford University School of Medicine, Stanford, California, USA – sequence: 27 givenname: Niaz surname: Banaei fullname: Banaei, Niaz organization: Department of Pathology, Stanford University School of Medicine, Stanford, California, USA – sequence: 28 givenname: Jayakumar surname: Rajadas fullname: Rajadas, Jayakumar organization: Bioengineering and Therapeutic Sciences, UCSF School of Pharmacy, University of California, San Francisco, San Francisco, California, USA – sequence: 29 givenname: Denise M surname: Monack fullname: Monack, Denise M organization: Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA – sequence: 30 givenname: Aijaz surname: Ahmed fullname: Ahmed, Aijaz organization: Department of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA – sequence: 31 givenname: Debashis surname: Sahoo fullname: Sahoo, Debashis organization: Department of Computer Science and Engineering, Jacobs School of Engineering, University of California, San Diego, La Jolla, California, USA – sequence: 32 givenname: Mark M surname: Davis fullname: Davis, Mark M organization: Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA – sequence: 33 givenname: Jeffrey S surname: Glenn fullname: Glenn, Jeffrey S organization: Department of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA – sequence: 34 givenname: Tom surname: Adomati fullname: Adomati, Tom organization: Institute of Immunology, Medical Faculty, University of Duisburg-Essen, Essen, Germany – sequence: 35 givenname: Karl S surname: Lang fullname: Lang, Karl S organization: Institute of Immunology, Medical Faculty, University of Duisburg-Essen, Essen, Germany – sequence: 36 givenname: Irving L surname: Weissman fullname: Weissman, Irving L email: Irv@stanford.edu, khasenkrug@nih.gov organization: Ludwig Cancer Center, Stanford University School of Medicine, Stanford, California, USA – sequence: 37 givenname: Kim J orcidid: 0000-0001-8523-4911 surname: Hasenkrug fullname: Hasenkrug, Kim J email: Irv@stanford.edu, khasenkrug@nih.gov organization: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA Irv@stanford.edu khasenkrug@nih.gov |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32576678$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkUFv1DAQhS1UREvpkSvKkUuKxxPHzgUJlkIXVaKq6NlynEk2JWsHO4vUf4-3Wyrqy1hv3nwz0nvNjnzwxNhb4OcAQn_Yfh7DOQfRYCn4C3YiQPJSSYCj_b-GUuTeMTtL6Y7nhwga-St2jEKqulb6hH2_nSMNu8kuY_BF6IvVl0oV61TY4jKkpVhtyP2aw-iX4obSHHyiYgnFtV02YSCfRRcGP-6n37CXvZ0SnT3WU3b79eLn6rK8-vFtvfp0VbpK4lI6WyuXL-Hg-haUbHgFTaMbxF4KV6Ek4EgWiFpuW67aykIjMGsaO02Ap2x94HbB3pk5jlsb702wo3kQQhyMjcvoJjKd7hX0CG1FotJtXuIstU2tOu5agVVmfTyw5l27pc6RX6KdnkGfd_y4MUP4YxSCBCEz4P0jIIbfO0qL2Y7J0TRZT2GXjKigblDVXGdrebC6GFKK1D-tAW72cZp9nOYhTiN49r_7_7Yn97_w8C-oYZvx |
| CitedBy_id | crossref_primary_10_1136_jitc_2022_004589 crossref_primary_10_3389_fimmu_2021_732530 crossref_primary_10_1016_j_tranon_2020_100862 crossref_primary_10_3389_fimmu_2021_739048 crossref_primary_10_1038_s41590_022_01132_2 crossref_primary_10_4155_ppa_2021_0005 crossref_primary_10_1016_j_jss_2022_10_093 crossref_primary_10_3389_fmed_2021_643235 crossref_primary_10_1016_j_jid_2022_04_029 crossref_primary_10_3389_fimmu_2021_652252 crossref_primary_10_3390_jcm10204798 crossref_primary_10_3390_cimb43030086 crossref_primary_10_1016_j_antiviral_2021_105226 crossref_primary_10_1128_IAI_00476_20 crossref_primary_10_1021_acs_bioconjchem_1c00437 crossref_primary_10_1128_mBio_01920_21 crossref_primary_10_1038_s41467_024_47963_5 crossref_primary_10_1007_s11010_022_04487_0 crossref_primary_10_1186_s12967_023_04667_6 crossref_primary_10_15252_embr_202152564 crossref_primary_10_1038_s41392_023_01365_z crossref_primary_10_1016_j_heliyon_2023_e17959 crossref_primary_10_3390_antib9030044 crossref_primary_10_3390_v14061144 crossref_primary_10_1016_j_isci_2022_105540 crossref_primary_10_3389_fimmu_2023_1227467 crossref_primary_10_1039_D2CB00076H |
| Cites_doi | 10.1073/pnas.1821218116 10.1074/jbc.274.2.559 10.1038/ni0602-499 10.1182/blood-2003-04-1078 10.1073/pnas.1418144112 10.1038/s41467-019-08637-9 10.1111/imm.12038 10.1084/jem.174.6.1425 10.1093/annonc/mdz006 10.4103/0976-500X.142464 10.1016/j.celrep.2020.03.058 10.1073/pnas.1424907112 10.1016/j.virol.2005.03.037 10.1016/j.cell.2009.05.046 10.1128/IAI.01426-15 10.1073/pnas.1121623109 10.1146/annurev-immunol-032713-120142 10.1200/JCO.18.02018 10.1038/nature18935 10.1038/nmeth.3337 10.1128/JVI.00605-16 10.1189/jlb.69.6.912 10.1126/scitranslmed.3001375 10.1128/JVI.01413-07 10.1073/pnas.1101398108 10.1056/NEJMoa1807315 10.1073/pnas.0900089106 10.1093/femsre/fuz012 10.1074/jbc.271.1.21 10.4049/jimmunol.180.10.6947 10.1016/s0962-8924(00)01906-1 10.1371/journal.pone.0128220 10.3389/fonc.2019.01380 10.1038/nature04444 10.3389/fimmu.2018.02985 10.4049/jimmunol.1403100 10.1007/978-3-7091-8276-5 10.1016/j.cell.2009.05.045 10.1128/IAI.73.2.1196-1203.2005 10.1101/2020.03.24.004655 10.1038/nri3712 10.1002/eji.201646875 10.1371/journal.ppat.1000090 10.1038/ncomms14802 10.1002/cyto.a.22778 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.1128/mBio.01293-20 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | Upregulation of CD47 Is a Host Checkpoint Response |
| EISSN | 2150-7511 |
| Editor | Vance, Russell |
| Editor_xml | – sequence: 1 givenname: Russell surname: Vance fullname: Vance, Russell |
| ExternalDocumentID | oai_doaj_org_article_d8f71f31b4e248b893caeb967d0cb234 10_1128_mBio_01293_20 32576678 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: F30 DK099017 – fundername: NIAID NIH HHS grantid: T32 AI007290 – fundername: NIAID NIH HHS grantid: F32 AI124558 – fundername: NIAID NIH HHS grantid: R01 AI155696 – fundername: NCATS NIH HHS grantid: UG3 TR003355 – fundername: NIAID NIH HHS grantid: U19 AI109662 – fundername: NCI NIH HHS grantid: R01 CA086017 – fundername: NIGMS NIH HHS grantid: R01 GM138385 – fundername: NIAID NIH HHS grantid: 1 F32 AI124558-01 – fundername: NIAID NIH HHS grantid: U19 AI057229 – fundername: ; – fundername: ; grantid: U01HL099999; U19AI109662 – fundername: ; grantid: R01CA086017 – fundername: ; grantid: 1 F32 AI124558-01 – fundername: ; grantid: F30DK099017 |
| GroupedDBID | --- 0R~ 53G 5VS AAFWJ AAUOK ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BTFSW CGR CUY CVF DIK E3Z EBS ECM EIF FRP GROUPED_DOAJ GX1 H13 HYE HZ~ KQ8 M48 M~E NPM O5R O5S O9- OK1 P2P PGMZT RHF RHI RNS RPM RSF AAYXX CITATION 7X8 5PM AFPKN |
| ID | FETCH-LOGICAL-c453t-ca67c33101cfb1759041998933f52c435e103ea1eeb0ab07b4a192303e83d8e13 |
| IEDL.DBID | RPM |
| ISSN | 2161-2129 |
| IngestDate | Tue Oct 22 15:12:32 EDT 2024 Tue Sep 17 21:20:23 EDT 2024 Fri Oct 25 00:12:43 EDT 2024 Fri Dec 06 02:00:53 EST 2024 Wed Oct 16 00:42:04 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | host response CD47 pathogen recognition receptors innate immunity immune checkpoint |
| Language | English |
| License | This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c453t-ca67c33101cfb1759041998933f52c435e103ea1eeb0ab07b4a192303e83d8e13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Irving L. Weissman and Kim J. Hasenkrug are co-senior authors, and both have the right to list their name last in their CV. The following authors contributed equally and have the right to list their name first in their CV: Michal Caspi Tal, Laughing Bear Torrez Dulgeroff, and Lara Myers. Michal Caspi Tal was listed first to acknowledge her supervisor role, followed by Laughing Bear Torrez Dulgeroff given her significant contribution to the final visualization of the data, followed Lara Myers. |
| ORCID | 0000-0001-8523-4911 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315125/ |
| PMID | 32576678 |
| PQID | 2416937608 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d8f71f31b4e248b893caeb967d0cb234 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7315125 proquest_miscellaneous_2416937608 crossref_primary_10_1128_mBio_01293_20 pubmed_primary_32576678 |
| PublicationCentury | 2000 |
| PublicationDate | 20200623 |
| PublicationDateYYYYMMDD | 2020-06-23 |
| PublicationDate_xml | – month: 6 year: 2020 text: 20200623 day: 23 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | mBio |
| PublicationTitleAlternate | mBio |
| PublicationYear | 2020 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | Steeves RA (e_1_3_3_42_2) 1969; 29 e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_32_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_40_2 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_25_2 e_1_3_3_46_2 e_1_3_3_2_2 e_1_3_3_20_2 De Veer MJ (e_1_3_3_33_2) 2001; 69 e_1_3_3_43_2 e_1_3_3_44_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_3_2 e_1_3_3_21_2 |
| References_xml | – ident: e_1_3_3_4_2 doi: 10.1073/pnas.1821218116 – ident: e_1_3_3_14_2 doi: 10.1074/jbc.274.2.559 – ident: e_1_3_3_27_2 doi: 10.1038/ni0602-499 – ident: e_1_3_3_25_2 doi: 10.1182/blood-2003-04-1078 – ident: e_1_3_3_36_2 doi: 10.1073/pnas.1418144112 – ident: e_1_3_3_18_2 doi: 10.1038/s41467-019-08637-9 – ident: e_1_3_3_20_2 doi: 10.1111/imm.12038 – ident: e_1_3_3_30_2 doi: 10.1084/jem.174.6.1425 – ident: e_1_3_3_7_2 doi: 10.1093/annonc/mdz006 – ident: e_1_3_3_28_2 doi: 10.4103/0976-500X.142464 – ident: e_1_3_3_24_2 doi: 10.1016/j.celrep.2020.03.058 – ident: e_1_3_3_41_2 doi: 10.1073/pnas.1424907112 – volume: 29 start-page: 1111 year: 1969 ident: e_1_3_3_42_2 article-title: Enhancement of spleen focus formation and virus replication in Friend virus-infected mice publication-title: Cancer Res contributor: fullname: Steeves RA – ident: e_1_3_3_21_2 doi: 10.1016/j.virol.2005.03.037 – ident: e_1_3_3_10_2 doi: 10.1016/j.cell.2009.05.046 – ident: e_1_3_3_37_2 doi: 10.1128/IAI.01426-15 – ident: e_1_3_3_9_2 doi: 10.1073/pnas.1121623109 – ident: e_1_3_3_16_2 doi: 10.1146/annurev-immunol-032713-120142 – ident: e_1_3_3_6_2 doi: 10.1200/JCO.18.02018 – ident: e_1_3_3_34_2 doi: 10.1038/nature18935 – ident: e_1_3_3_45_2 doi: 10.1038/nmeth.3337 – ident: e_1_3_3_17_2 doi: 10.1128/JVI.00605-16 – volume: 69 start-page: 912 year: 2001 ident: e_1_3_3_33_2 article-title: Functional classification of interferon-stimulated genes identified using microarrays publication-title: J Leukoc Biol doi: 10.1189/jlb.69.6.912 contributor: fullname: De Veer MJ – ident: e_1_3_3_12_2 doi: 10.1126/scitranslmed.3001375 – ident: e_1_3_3_23_2 doi: 10.1128/JVI.01413-07 – ident: e_1_3_3_19_2 doi: 10.1073/pnas.1101398108 – ident: e_1_3_3_5_2 doi: 10.1056/NEJMoa1807315 – ident: e_1_3_3_11_2 doi: 10.1073/pnas.0900089106 – ident: e_1_3_3_22_2 doi: 10.1093/femsre/fuz012 – ident: e_1_3_3_13_2 doi: 10.1074/jbc.271.1.21 – ident: e_1_3_3_38_2 doi: 10.4049/jimmunol.180.10.6947 – ident: e_1_3_3_15_2 doi: 10.1016/s0962-8924(00)01906-1 – ident: e_1_3_3_39_2 doi: 10.1371/journal.pone.0128220 – ident: e_1_3_3_8_2 doi: 10.3389/fonc.2019.01380 – ident: e_1_3_3_2_2 doi: 10.1038/nature04444 – ident: e_1_3_3_40_2 doi: 10.3389/fimmu.2018.02985 – ident: e_1_3_3_26_2 doi: 10.4049/jimmunol.1403100 – ident: e_1_3_3_31_2 doi: 10.1007/978-3-7091-8276-5 – ident: e_1_3_3_32_2 doi: 10.1016/j.cell.2009.05.045 – ident: e_1_3_3_44_2 doi: 10.1128/IAI.73.2.1196-1203.2005 – ident: e_1_3_3_46_2 doi: 10.1101/2020.03.24.004655 – ident: e_1_3_3_29_2 doi: 10.1038/nri3712 – ident: e_1_3_3_3_2 doi: 10.1002/eji.201646875 – ident: e_1_3_3_43_2 doi: 10.1371/journal.ppat.1000090 – ident: e_1_3_3_35_2 doi: 10.1038/ncomms14802 – ident: e_1_3_3_47_2 doi: 10.1002/cyto.a.22778 |
| SSID | ssj0000331830 |
| Score | 2.458669 |
| Snippet | It is well understood that the adaptive immune response to infectious agents includes a modulating suppressive component as well as an activating component. We... Immune responses to infectious agents are initiated when a pathogen or its components bind to pattern recognition receptors (PRRs). PRR binding sets off a... ABSTRACT It is well understood that the adaptive immune response to infectious agents includes a modulating suppressive component as well as an activating... |
| SourceID | doaj pubmedcentral proquest crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| SubjectTerms | A549 Cells Adaptive Immunity - immunology Animals Betacoronavirus - immunology CD47 CD47 Antigen - genetics CD47 Antigen - metabolism Cell Line, Tumor Cytokines - immunology Female host response Host-Microbe Biology Humans immune checkpoint Immunity, Innate - immunology Immunomodulation - immunology innate immunity Lymphocytic choriomeningitis virus - immunology Male Mice Mice, Inbred C57BL Mice, Knockout Mycobacterium tuberculosis - immunology pathogen recognition receptors Receptors, Pattern Recognition - immunology SARS-CoV-2 Up-Regulation - immunology |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3BatwwEBUlUOilNE3aukmDAqE3N5JGtuRjs0nY5BBK6EJuwpJHZCm1lqxz6N9HsnbDbin0kqttsPxm0Lyxn98QciI8cuGSFIfrrpRY21JLbktwqurAesVwFMje1NOZvL6r7jZGfSVNWLYHzsCddtor7oFbiUJqG8ura9E2teqYswKyEygTG83UuAdDylW2NtUU-vT32Tx8S29doEyzvTeK0OjV_y-C-bdOcqPwXL4jb1eMkX7PK90lr7B_T17nGZJ_9sj1bPGQ58lHhGnwdHIuFb1a0pZOw3Kgk3t0vxZh3g_0NuthkQ6B_ojML8TkobdrBVHo98ns8uLnZFquBiSUTlYwlK6tlYtPyrjzNvKAhsn0y1wD4CvhIhFCzgBbjmhZa5mysk2ELh7T0Gnk8IHs9KHHT4Q2nXI1VgiNriT3Ee7OW_BtbIcsxh2zIF_XiJlF9sEwY_8gtEnQmhFaI1hBzhKezxcl--rxQAyqWQXV_C-oBTleR8PEdE_fMNoew-PSRMJRN0nIowvyMUfn-VaQmqdYfAuituK2tZbtM_38frTUVpCYT_X5JRZ_QN6I1JSzuhRwSHaGh0f8EpnLYI_GJH0CwTvsQQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELagCIlLxbsBioyEuKX4ldg5INQuVEslEKpYqTcrdsbtqhBvd1OJ_nvGSbawVQ9cnSi2Z8aeb5zPM4S8FQG48ImKw02TKyhdbhR3ufS6aKQLmkFPkP1WTmfq6KQ4-ZtSaBTg6tbQLtWTmi1_7v2-uPqIC_7DcAHGvP91MI976UBFos7vknsCnWJid30dkX6_KctkvOnERSDGyXHDrtYZN29-YcND9Yn8b0OfN0mU_3ilw4dke4STdH_Q_yNyB9rH5P5QYPLqCTmaLZZDsXkUP42BTj4pTb-saE2ncdXRyRn480Wctx09HsiyQLtIvyMsjGhZ9HhNL4rtUzI7_PxjMs3H6gm5V4Xscl-X2uOsGffBIUiomEr36SopQyE8oiTgTELNARyrHdNO1QntYZuRjQEun5GtNrawQ2jVaF9CAbIyheKBO9UEJ0ONsZID3E4z8m4tMbsYkmTYPrgQxibR2l60VrCMHCR5Xr-Uclv3DXF5aselYhsTNA8SewGhjMMR-xpcVeqGeSekysibtTYsroX0g6NuIV6uLKKRskosH5OR54N2rruSKbJCz5wRvaG3jbFsPmnnZ32-bS0TLCpe_O8sX5IHIkXlrMyFfEW2uuUl7CJ06dzr3ij_AAoU6sc priority: 102 providerName: Scholars Portal |
| Title | Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32576678 https://search.proquest.com/docview/2416937608 https://pubmed.ncbi.nlm.nih.gov/PMC7315125 https://doaj.org/article/d8f71f31b4e248b893caeb967d0cb234 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe2SaC9IL7JgMlIiLe0_krsPLLCKJOGpolKfbNi57xV0Lhqs4f999hOM7WIJ1784CTy5e7k-13y8x1CH5kDymyk4lDV5AJKkytBTc6tLBpunCSQCLI_yulMXMyL-QEqhrMwibRvzWLU_l6O2sVt4laulnY88MTGV5cTyWOcKsaH6DCE350UPW2_PLopGeppMjVeni38KH5w4cEnjtFjHkF2GRur7YSiVLH_XzDzb7bkTvg5f4qebHEj_tzL9wwdQPscPeo7Sd6_QBez1brvKh_0jL3Dky9C4u8bXOOp33R4cgv218ov2g5f96xYwJ3HVwH_-eBC-HrgEfn2JZqdf_05mebbNgm5FQXvcluX0oaXJtQ6E9BARUQ8OFdx7gpmAxwCSjjUFMCQ2hBpRB1hXZhTvFFA-St01PoW3iBcNdKWUACvVCGoo0Y0znBXh6TIQNg3M_Rp0Jhe9dUwdMoimNJRyzppWTOSobOoz4ebYhHrNOHXN3prSt0oJ6njYRVgQpkgsa3BVKVsiDWMiwx9GKyhg9PHPxl1C_5uowPsKKtI51EZet1b52GpwboZknt225Nl_0rws1RYe-tXJ__95Ft0zGI-Tsqc8XfoqFvfwfsAWjpzmpL9MH6b0zBeCnWa3PYPhybu-w |
| link.rule.ids | 230,314,727,780,784,864,885,2102,24318,27924,27925,53791,53793 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIqAXxKt0eRoJccuuX4mdI12otqWtqqor9WbFjk1XdOPVbnrg32M7m2oXceLqJLIz88nzTfJ5BuAzdZZQE6U4RNYZt4XOJCc6Y0bkNdNOYJsEsufFZMpPrvPrHcj7szBJtG_0bNjczofN7CZpKxdzM-p1YqOLs7FgMU7lowfwMGeiJBtJetqAWQQq7itqUjmaH878MH5yYQEVe_CYRZpdxNZqG8Eo1ez_F9H8Wy-5EYCOnsHTNXNEX7sVPocd27yAR10vyd8v4WS6WHZ95YOlkXdo_I0LdLxCFZr4VYvGN9b8WvhZ06LLThdrUevRRWCAPoAIXfZKIt-8gunR96vxJFs3SsgMz1mbmaoQJrw0JsbpwAdKzOPRuZIxl1MTCJElmNmKWKtxpbHQvIrELoxJVktL2D7sNr6xB4DKWpjC5paVMufEEc1rp5mrQlqkbdg5B_Clt5hadPUwVMojqFTRyipZWVE8gMNoz_ubYhnrNOCXP9XamaqWThDHwiyWcqnDik1ldVmIGhtNGR_Ap94bKsA-_suoGuvvVioQj6KMgh45gNedd-6n6r07ALHlt621bF8JSEultdfIevPfT36EJ5Ors1N1enz-4y3s0Zid4yKj7B3stss7-z5QmFZ_SID9A2mS75A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagiKoXVJ5NeRkJccvGr8TOkW5ZbQtUq4qVerNix6arduNoNz3w77GdTbVbceLqJLIz88nzTfxlBoDPxBpMdJDiYFGnzBQqFQyrlGqe11RZjkwUyF4U0zk7v8qvtlp9RdG-VotRc7scNYvrqK1slzobdGLZ7OeY0xCn8qytbfYYPMmpB9lWoh43YRrAioaqmkRky5OFG4XPLtQj4wDs00C1i9BebSsgxbr9_yKbDzWTW0Focgiebdgj_Nqv8jl4ZJoX4GnfT_LPS3A-b1d9b3lvbegsHJ8yDs_WsIJTt-7g-Nrom9Ytmg5e9tpYAzsHZ54FOg8keDmoiVzzCswn336Np-mmWUKqWU67VFcF1_6lEdZWeU5QIhZ-nysptTnRnhQZjKipsDEKVQpxxapA7vyYoLUwmL4Ge41rzBGAZc11YXJDS5EzbLFitVXUVj41Usbvngn4MlhMtn1NDBlzCSJksLKMVpYEJeAk2PP-plDKOg641W-5caisheXYUj-LIUwov2JdGVUWvEZaEcoS8GnwhvTQD-cZVWPc3Vp68lGUQdQjEvCm9879VIN3E8B3_Lazlt0rHm2xvPYGXcf__eRHsD87ncgfZxff34IDEhJ0VKSEvgN73erOvPcsplMfIl7_AuJ58KM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Upregulation+of+CD47+Is+a+Host+Checkpoint+Response+to+Pathogen+Recognition&rft.jtitle=mBio&rft.au=Tal%2C+Michal+Caspi&rft.au=Torrez+Dulgeroff%2C+Laughing+Bear&rft.au=Myers%2C+Lara&rft.au=Cham%2C+Lamin+B.&rft.date=2020-06-23&rft.issn=2161-2129&rft.eissn=2150-7511&rft.volume=11&rft.issue=3&rft_id=info:doi/10.1128%2FmBio.01293-20&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_mBio_01293_20 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2161-2129&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2161-2129&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2161-2129&client=summon |